Intracranial hemorrhage caused by non-vitamin K antagonist oral anticoagulants (NOACs) - Multicenter retrospective cohort study in Japan

Circulation Journal

Volumn 79, Issue 5, 2015, Pages 1018-1023

  Saji, Naoki ^a   Kimura, Kazumi ^b   Aoki, Junya ^b   Uemura, Junichi ^a   Sakamoto, Yuki ^b  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b NIPPON MEDICAL SCHOOL GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Atrial fibrillation; Cerebral hemorrhage; Intracranial hemorrhage; Non vitamin K antagonist oral anticoagulants

Indexed keywords

ANTITHROMBOCYTIC AGENT; APIXABAN; CREATININE; DABIGATRAN; PROTHROMBIN COMPLEX; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; VITAMIN K GROUP;

AGED; ARTICLE; BRAIN HEMORRHAGE; CHADS2 SCORE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; DATA EXTRACTION; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; MORTALITY; MULTICENTER STUDY; QUESTIONNAIRE; RETROSPECTIVE STUDY; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA; VERY ELDERLY; ATRIAL FIBRILLATION; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; EPIDEMIOLOGY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HOSPITAL MORTALITY; HUMANS; INTRACRANIAL HEMORRHAGES; JAPAN; MALE; RETROSPECTIVE STUDIES; VITAMIN K; WARFARIN;

EID: 84928485176     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-1209     Document Type: Article

References (33)

1. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151: 297-305
2. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 Focused update of the ESC Guidelines for the Management of Atrial Fibrillation: An update of the 2010 ESC Guidelines for the Management of Atrial Fibrillation: Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747
3. January CT, Wann LS, Alpert JS, Calkins H, Cleveland JC, Cigarroa JE, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014; 130: 2071-2104
4. Inoue H, Atarashi H, Okumura K, Yamashita T, Kumagai N, Origasa H. Thromboembolic events in paroxysmal vs. Permanent non-valvular atrial fibrillation. Circ J 2014; 78: 2388-2393
5. Hart RG, Diener HC, Yang S, Connolly SJ, Wallentin L, Reilly PA, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: The RE-LY trial. Stroke 2012; 43: 1511-1517
6. Kosiuk J, Koutalas E, Doering M, Nedios S, Sommer P, Rolf S, et al. Comparison of dabigatran and uninterrupted warfarin in patients wsith atrial fibrillation undergoing cardiac rhythm device implantations. Circ J 2014; 78: 2402-2407
7. Tanahashi N, Hori M, Matsumoto M, Momomura S, Uchiyama S, Goto S, et al. Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation for the secondary prevention of stroke: A subgroup analysis of J-ROCKET AF. J Stroke Cerebrovasc Dis 2013; 22: 1317-1325
8. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet 2014; 383: 955-962
9. Cameron C, Coyle D, Richter T, Kelly S, Gauthier K, Steiner S, et al. Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. BMJ Open 2014; 4: e004301, doi:10.1136/bmjopen-2013-004301
10. Sabir I, Khavandi K, Brownrigg J, Camm AJ. Oral anticoagulants for Asian patients with atrial fibrillation. Nat Rev Cardiol 2014; 11: 290-303
11. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625-651
12. Kuwashiro T, Yasaka M, Itabashi R, Nakagaki H, Miyashita F, Naritomi H, et al. Enlargement of acute intracerebral hematomas in patients on long-term warfarin treatment. Cerebrovasc Dis 2010; 29: 446-453
13. Toyoda K, Yasaka M, Nagata K, Nagao T, Gotoh J, Sakamoto T, et al. Antithrombotic therapy influences location, enlargement, and mortality from intracerebral hemorrhage: The Bleeding with Antithrombotic Therapy (BAT) retrospective study. Cerebrovasc Dis 2009; 27: 151-159
14. Hernandez I, Baik SH, Piñera A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med 2015; 175: 18-24
15. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for non-valvular atrial fibrillation. Circulation 2015; 131: 157-164
16. Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 2007; 50: 309-315
17. Hankey GJ, Stevens SR, Piccini JP, Lokhnygina Y, Mahaffey KW, Halperin JL, et al. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: The rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke 2014; 45: 1304-1312
18. Witt DM, Delate T, Hylek EM, Clark NP, Crowther MA, Dentali F, et al. Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes. Thromb Res 2013; 132: 770-775
19. Dowlatshahi D, Butcher KS, Asdaghi N, Nahirniak S, Bernbaum ML, Giulivi A, et al. Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke 2012; 43: 1812-1817
20. Alonso A, Bengtson LG, MacLehose RF, Lutsey PL, Chen LY, Lakshminarayan K. Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin. Stroke 2014; 45: 2286-2291
21. Chen YW, Tang SC, Tsai LK, Yeh SJ, Chiou HY, Yip PK, et al. Pre-ICH warfarin use, not antiplatelets, increased case fatality in spontaneous ICH patients. Eur J Neurol 2013; 20: 1128-1134
22. Horstmann S, Rizos T, Lauseker M, Möhlenbruch M, Jenetzky E, Hacke W, et al. Intracerebral hemorrhage during anticoagulation with vitamin K antagonists: A consecutive observational study. J Neurol 2013; 260: 2046-2051
23. Liotta EM, Garg RK, Temes RE, John S, Lee VH, Bleck TP, et al. Warfarin-associated intracerebral hemorrhage is inadequately treated at community emergency departments. Stroke 2012; 43: 2503-2505
24. Hagii J, Tomita H, Metoki N, Saito S, Shiroto H, Hitomi H, et al. Characteristics of intracerebral hemorrhage during rivaroxaban treatment: Comparison with those during warfarin. Stroke 2014; 45: 2805-2807
25. Komori M, Yasaka M, Kokuba K, Matsuoka H, Fujimoto S, Yoshida M, et al. Intracranial hemorrhage during dabigatran treatment. Circ J 2014; 78: 1335-1341
26. Simonsen CZ, Steiner T, Tietze A, Damgaard D. Dabigatranrelated intracerebral hemorrhage resulting in hematoma expansion. J Stroke Cerebrovasc Dis 2014; 23: e133-e134, doi:10.1016/j.jstrokecerebrovasdis.2013.08.011
27. Hankey GJ. Intracranial hemorrhage and novel anticoagulants for atrial fibrillation: What have we learned? Curr Cardiol Rep 2014; 16: 480
28. Chatterjee S, Sardar P, Biondi-Zoccai G, Kumbhani DJ. New oral anticoagulants and the risk of intracranial hemorrhage: Traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. JAMA Neurol 2013; 70: 1486-1490
29. Kono S, Yamashita T, Deguchi K, Omote Y, Yunoki T, Sato K, et al. Rivaroxaban and apixaban reduce hemorrhagic transformation after thrombolysis by protection of neurovascular unit in rat. Stroke 2014; 45: 2404-2410
30. Laliberté F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin 2014; 30: 1317-1325
31. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al. Rivaroxaban vs. Warfarin in Japanese patients with non-valvular atrial fibrillation in relation to age. Circ J 2014; 78: 1349-1356
32. Okumura K, Inoue H, Atarashi H, Yamashita T, Tomita H, Origasa H, et al. Validation of CHA2DS2-VASc and HAS-BLED scores in Japanese patients with nonvalvular atrial fibrillation: An analysis of the J-RHYTHM Registry. Circ J 2014; 78: 1593-1599
33. Harrington AR, Armstrong EP, Nolan PE, Malone DC. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke 2013; 44: 1676-1681.